Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Titel:
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Auteur:
Bardia, A. Messersmith, W.A. Kio, E.A. Berlin, J.D. Vahdat, L. Masters, G.A. Moroose, R. Santin, A.D. Kalinsky, K. Picozzi, V. O'Shaughnessy, J. Gray, J.E. Komiya, T. Lang, J.M. Chang, J.C. Starodub, A. Goldenberg, D.M. Sharkey, R.M. Maliakal, P. Hong, Q. Wegener, W.A. Goswami, T. Ocean, A.J.